tiprankstipranks
Trending News
More News >
Compumedics Limited (AU:CMP)
ASX:CMP
Australian Market

Compumedics Limited (CMP) AI Stock Analysis

Compare
4 Followers

Top Page

AU

Compumedics Limited

(Sydney:CMP)

Rating:50Neutral
Price Target:
AU$0.50
▲(78.57%Upside)
Compumedics Limited's stock score is primarily driven by its financial performance and technical analysis. Positive revenue growth is overshadowed by ongoing profitability issues and negative market momentum. The lack of earnings call insights and corporate events limits further assessment.

Compumedics Limited (CMP) vs. iShares MSCI Australia ETF (EWA)

Compumedics Limited Business Overview & Revenue Model

Company DescriptionCompumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Grael 4K PSG:EEG amplifiers; Somté PSG; Siesta 802, an ambulatory recording device; Okti; Grael PSG; Grael DC; Somfit/Somfit Pro, a wearable device; TCM5 FLEX Transcutaneous monitor; and Somté, an investigative tool. The company also provides neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Xegis Forte EMG/EP; and Xegis G:NEO 2 Channel EMG/EP systems. In addition, it offers software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that provides integrated hardware and software solutions for sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and HD Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, summit IP, and persyst software products. Further, the company provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and a range of consumables and supplies for diagnostic and research solutions. The company was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited operates as a subsidiary of D & DJ Burton Holdings Pty Ltd.
How the Company Makes MoneyCompumedics Limited generates revenue through the sale of its medical devices and software solutions. The company's revenue streams include direct sales to hospitals and clinics, as well as through distributors and partnerships with healthcare providers globally. Compumedics also earns income from ongoing service and support contracts, which involve maintenance and updates for their diagnostic equipment. Additionally, the company invests in research and development to introduce new technologies and stay competitive in the market, which can lead to increased sales and expanded market reach. Strategic collaborations and partnerships further enhance their market presence and contribute to their financial performance.

Compumedics Limited Financial Statement Overview

Summary
Compumedics Limited is showing positive revenue growth and stable gross profit margins, indicating potential for future performance improvements. However, the company faces significant challenges with ongoing net losses, negative EBIT, and negative free cash flow. The balanced capital structure with moderate leverage is a positive aspect, but improving profitability is essential for financial stability.
Income Statement
65
Positive
Compumedics Limited has shown a positive revenue growth rate of 17.23% from 2023 to 2024, indicating a recovery trend. However, the company continues to experience negative net income and EBIT, resulting in negative net and EBIT margins. Gross profit margins have remained relatively stable, suggesting efficient cost management at the gross level but challenges in operational efficiency.
Balance Sheet
60
Neutral
The company's debt-to-equity ratio has increased slightly, indicating a moderate level of leverage. The equity ratio stands at 45.11%, which reflects a balanced capital structure but a decrease from previous years. Return on equity remains negative due to net losses, highlighting profitability challenges.
Cash Flow
55
Neutral
Compumedics Limited's free cash flow has improved from 2023 to 2024 but remains negative. The operating cash flow to net income ratio is favorable, suggesting that cash flow generation relative to net income is strong. However, the overall negative free cash flow indicates ongoing challenges in generating sufficient cash from operations.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
46.83M49.72M42.41M37.76M35.74M35.07M
Gross Profit
24.12M26.07M21.59M19.32M19.16M18.01M
EBIT
-1.47M-269.00K-3.53M137.00K398.00K-756.00K
EBITDA
551.00K2.79M-5.05M1.35M2.56M-5.42M
Net Income Common Stockholders
-1.75M-338.00K-6.12M1.36M998.00K-5.84M
Balance SheetCash, Cash Equivalents and Short-Term Investments
3.96M1.89M3.80M7.29M6.77M6.41M
Total Assets
47.82M40.36M41.18M41.71M38.55M35.53M
Total Debt
12.56M8.58M9.47M6.55M5.82M4.80M
Net Debt
8.59M6.69M5.67M-746.00K-950.00K-1.61M
Total Liabilities
26.43M22.15M22.89M18.12M16.39M13.73M
Stockholders Equity
21.39M18.21M18.29M23.59M22.16M21.79M
Cash FlowFree Cash Flow
-1.57M-986.00K-4.36M302.00K-230.00K1.15M
Operating Cash Flow
-1.30M2.00M49.00K3.29M1.32M5.38M
Investing Cash Flow
-5.95M-2.99M-4.41M-2.98M-1.55M-4.23M
Financing Cash Flow
6.83M-1.49M-1.00M1.61M-179.00K448.00K

Compumedics Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.28
Price Trends
50DMA
0.30
Negative
100DMA
0.29
Negative
200DMA
0.29
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
46.58
Neutral
STOCH
19.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CMP, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.30, and below the 200-day MA of 0.29, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.58 is Neutral, neither overbought nor oversold. The STOCH value of 19.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CMP.

Compumedics Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
AUCMP
50
Neutral
AU$54.78M-8.08%-5.62%-225.71%
$11.41B46.6220.61%1.61%
$76.11B26.6715.38%1.85%
$848.17M72.509.23%
AURMD
79
Outperform
AU$56.78B27.9325.23%0.85%10.54%38.69%
AURHT
61
Neutral
AU$18.38M140.00-3.11%89.13%69.57%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:CMP
Compumedics Limited
0.28
-0.02
-6.67%
CHEOF
Cochlear
174.05
-41.96
-19.43%
CMXHF
CSL
151.50
-33.15
-17.95%
NNCSF
Nanosonics Limited
2.61
0.62
31.16%
AU:RHT
Resonance Health Ltd
0.04
-0.02
-33.33%
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
38.23
6.84
21.79%

Compumedics Limited Corporate Events

Compumedics Adjusts FY25 Financial Guidance and Confirms FY26 Outlook
May 21, 2025

Compumedics Limited announced a correction to its financial guidance for FY25, expecting sales orders to exceed $60 million, with reported revenues between $50 million and $55 million, which is below the previously advised $55 million. The company anticipates an EBITDA of about $3 million for FY25, down from the previously advised $5 million. Looking ahead, Compumedics confirms FY26 revenue guidance of at least $70 million, driven by the shipment of MEG orders, with an expected EBITDA of at least $9 million.

Compumedics Secures $1M Somfit Contract with Leading US CRO
May 21, 2025

Compumedics Limited has secured a significant contract worth $1 million for its Somfit device with a leading pharmaceutical Contract Research Organisation in the USA. This sale is part of Compumedics’ strategy to expand beyond the home sleep testing market into pharmaceutical clinical trials, leveraging Somfit’s ability to directly track brain signals for accurate sleep architecture analysis. The contract highlights the company’s strong growth in the USA, with sales orders reaching $12 million this year, a 130% increase from the previous year. Compumedics anticipates continued growth, projecting sales orders over $60 million for FY25, although revenue and EBITDA expectations have been adjusted due to the rapid business expansion.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.